Actavis CEO Says Health Law May Boost Generics Use
Feb. 15 (Bloomberg) -- Paul Bisaro, chief executive officer of Actavis Inc., talks about the impact of the U.S. Affordable Care Act on the pharmaceutical industry, so-called biosimilars, generic versions of biotechnology drugs, and the outlook for growth. He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line." (Source: Bloomberg)
Most Recent Videos
Decaux: U.K. Slowdown to Impact U.K. Advertising Market
29:53 - JCDecaux SA announced its 2016 half year financial results of an increase of 10.8% to 1,617.3 million euros. Co-CEO Jean-Francois Decaux told Bloomberg's Anna Edwards and Manus Cranny on "Countdown" that the company expects a possible slowdown for the U.K. economy after Brexit, which will affect the local advertising market.